{
    "clinical_study": {
        "@rank": "100650", 
        "arm_group": [
            {
                "arm_group_label": "MK-3102", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial will assess the safety and efficacy of MK-3102 compared with the sulfonylurea,\n      glimepiride, in Type 2 diabetes mellitus participants with inadequate glycemic control on\n      metformin monotherapy."
        }, 
        "brief_title": "A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with Type 2 diabetes mellitus\n\n          -  On a stable dose of metformin (\u22651500 mg/day) for at least 12 weeks with inadequate\n             glycemic control\n\n          -  Females of reproductive potential agree to remain abstinent or use or have their\n             partner use acceptable methods of birth control\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  Treated with any antihyperglycemic agents (AHA) therapies other than the\n             protocol-required metformin within the prior 12 weeks of study participation or with\n             MK-3102 at any time prior to signing informed consent\n\n          -  On a weight loss program and is not in the maintenance phase or has\n\n        started a weight loss medication in the past 6 months or has undergone bariatric surgery\n        within 12 months prior to study participation\n\n          -  Medical history of active liver disease (other than non-alcoholic\n\n        hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis,\n        or symptomatic gallbladder disease\n\n          -  Human immunodeficiency virus\n\n          -  New or worsening coronary heart disease, congestive heart failure, myocardial\n             infarction, unstable angina, coronary artery intervention, stroke or transient\n             ischemic neurological disorder within the past 3 months\n\n          -  History of malignancy \u22645 years prior to study participation except for adequately\n             treated basal cell or squamous cell skin cancer, or in situ\n\n        cervical cancer\n\n          -  Clinically important hematological disorder (such as aplastic anemia,\n\n        myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n          -  Pregnant or breast-feeding, or is expecting to conceive or donate eggs\n\n        during the trial, including 21 days following the last dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "680", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682759", 
            "org_study_id": "3102-016", 
            "secondary_id": "MK-3102-016"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-3102", 
                "description": "MK-3102 (25 mg) will be administered in a blinded manner as one capsule once a week (q.w.)", 
                "intervention_name": "MK-3102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "description": "Placebo matching MK-3102 (25 mg)", 
                "intervention_name": "MK-3102 Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Glimepiride", 
                "description": "Glimepiride (1 mg and/or 2 mg tablets).\nDuring the double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AMARYL\u00ae", 
                    "GLIMY"
                ]
            }, 
            {
                "arm_group_label": "MK-3102", 
                "description": "Placebos matching glimepiride 1 mg and/or 2 mg", 
                "intervention_name": "Glimepiride Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Glimepiride"
                ], 
                "description": "Open-label", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-3102", 
                    "Glimepiride"
                ], 
                "description": "Insulin glargine can be used for rescue therapy, if glycemic control is not maintained.", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Glargine", 
                "Insulin", 
                "Metformin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "diabetes", 
        "lastchanged_date": "May 30, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in Hemoglobin A1C at Week 54", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 54"
            }, 
            {
                "measure": "Percentage of Participants Who Experienced at Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 57"
            }, 
            {
                "measure": "Percentage of Participants Who Discontinued from the Study Due to an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 54"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Croatia", 
                "Germany", 
                "Hungary", 
                "Korea, Republic of", 
                "Lebanon", 
                "Lithuania", 
                "Malaysia", 
                "Poland", 
                "Romania"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682759"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Fasting Plasma Glucose at Week 54", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 54"
            }, 
            {
                "measure": "Number of Participants Achieving a Hemoglobin A1C of <6.5% and <7.0% at Week 54", 
                "safety_issue": "No", 
                "time_frame": "Week 54"
            }, 
            {
                "measure": "Number of Participants with an Adverse Event of Symptomatic Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 54"
            }, 
            {
                "measure": "Change in Body Weight from Baseline at Week 54", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 54"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}